DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2258435/what-s-in-store-for-biogen-biib-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-2258435 Apr 19, 2024 - Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate. 0

https://www.zacks.com/stock/news/2257993/biotech-stock-roundup-regn-sage-nmra-down-on-updates-itci-gains-on-study-success?cid=CS-ZC-FT-analyst_blog|stock_roundup-2257993 Apr 18, 2024 - Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates. 0

https://www.zacks.com/stock/news/2257958/sage-sage-down-20-on-parkinson-s-study-missing-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2257958 Apr 18, 2024 - Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo. 0

https://www.zacks.com/stock/news/2257742/sage-therapeutics-inc-sage-may-report-negative-earnings-know-the-trend-ahead-of-next-week-s-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2257742 Apr 18, 2024 - Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://seekingalpha.com/news/4090522-bofa-downgrades-sage-to-underperform-cites-failed-parkinsons-study?source=feed_sector_healthcare Apr 17, 2024 - BoA has downgraded Sage (SAGE) to underperform, citing the company’s failed Phase 2 study for its drug SAGE-718 in the treatment of cognitive impairment in Parkinson’s disease. 0

https://www.zacks.com/stock/news/2241524/why-is-sage-therapeutics-inc-sage-down-22-since-last-earnings-report?cid=CS-ZC-FT-realtime_blog-2241524 Mar 15, 2024 - Sage Therapeutics, Inc. (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. 0

https://www.zacks.com/stock/news/2231190/sage-group-plc-sgpyy-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2231190 Feb 23, 2024 - Sage Group PLC (SGPYY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). 0

https://www.zacks.com/stock/news/2227123/sage-therapeutics-sage-q4-earnings-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2227123 Feb 15, 2024 - Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae. Stock rise. 0

https://www.zacks.com/stock/news/2223511/can-biogen-biib-keep-the-beat-streak-alive-in-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2223511 Feb 08, 2024 - Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen. 0

https://www.zacks.com/stock/news/2222623/will-sage-therapeutics-inc-sage-report-negative-earnings-next-week-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2222623 Feb 07, 2024 - Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0